Assessment of outcomes in non-squamous lung cancer patients after chemotherapy failure in Brazil

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study involves a retrospective review of medical records from patients diagnosed with advanced non-squamous non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy. It aims to evaluate clinical practices and outcomes in real-world settings for these patients, focusing on those who have received at least one line of systemic treatment after chemotherapy failure. The study will analyze various subtypes of NSCLC based on genomic mutations and treatment history, providing insights into the effectiveness of subsequent therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Confirmed diagnosis of non-squamous NSCLC, Stage IIIB/IIIC incurable or IV/M1.
* Age ≥ 18 years at diagnosis of advanced/metastatic disease.

AGA Cohort: Presence of actionable mutations and all of the following:

* failure of platinum-based chemotherapy,
* failure of ≥ 1 line of approved target therapy or no targeted therapy available at the clinic,
* additional systemic treatment after platinum + target therapy combination.

Non-AGA Cohort: Absence of actionable mutations and all of the following:

* failure of platinum-based chemotherapy,
* failure of immunotherapy concurrent or sequential to platinum,
* additional systemic treatment after platinum + immunotherapy combination.

Exclusion Criteria

* Patients with evidence of other primary malignancies (except basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both study cohorts.
* Patients who participated in a clinical investigational study for the treatment of any cancer, including NSCLC, or any early access program from 2018 onwards.

Where it's running

• Research Site
  Natal, Rio Grande do Norte, Brazil Recruiting
• Research Site
  São Paulo, Brazil Recruiting
• Research Site
  São Paulo, Brazil Recruiting
• Research Site
  São Paulo, Brazil Recruiting
• Research Site
  São Paulo, Brazil Recruiting
• Research Site
  Belo Horizonte, Minas Gerais, Brazil Not yet recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Aglatimagene Besadenovec with Prodrug and Pembrolizumab vs Docetaxel for Advanced Non-Squamous NSCLC

  This phase 3 trial tests whether giving aglatimagene besadenovec with a prodrug and pembrolizumab works better than standard chemotherapy (docetaxel) for adults with stage IV non-squamous NSCLC that progressed on pembrolizumab.

  Recruiting Phase 3 Candel Therapeutics, Inc. · New York, New York · NCT07660094

• IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)

  A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.

  Recruiting at 6 sites Phase 1/2 InduPro, Inc. · Los Angeles, California and 5 other locations · NCT07602842

• BL-M07D1 plus pembrolizumab for advanced HER2‑overexpressing non-squamous NSCLC

  This treatment combines BL-M07D1 with pembrolizumab to see if it helps people with unresectable locally advanced or metastatic HER2‑overexpressing non‑squamous non‑small cell lung cancer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07264816

• BL-M07D1 versus pembrolizumab-plus-platinum chemo for first-line HER2‑mutant advanced non-squamous lung cancer

  This trial will test whether BL-M07D1 works better than pembrolizumab combined with platinum chemotherapy as the first treatment for people with HER2‑mutant advanced or metastatic non-squamous non-small cell lung cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07178795

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.